Breast Cancer News

News

For Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer, Targeted Therapy Plus Endocrine Therapy Was Highly Ranked in Meta-Analysis

05/11/2022

Ellen Kurek ;

Researchers conducted an information theoretic network meta-analysis to rank treatment regimens for hormone receptor-positive, ERBB2-negative metastatic breast cancer by their comparative effectiveness.

Researchers conducted an...

05/11/2022

Journal of Clinical Pathways

News

Cost-Effectiveness of Margetuximab vs Trastuzumab for ERBB2–Positive, Advanced Breast Cancer

04/14/2022

Janelle Bradley ;

Study findings suggest margetuximab plus chemotherapy is not cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast cancer.

Study findings suggest...

04/14/2022

Journal of Clinical Pathways

News

Genomic Assays Aid Individualized Treatment Decision-Making for HR–Positive, HER2–Negative Breast Cancer

04/14/2022

Ellen Kurek ;

Greater reliance on genomic assays has reduced the use of adjuvant chemotherapy in women with early-stage, HR–positive, HER2–negative breast cancer who are free of axillary node disease and at low genomic risk, according to a recent study.

Greater reliance on genomic...

04/14/2022

Journal of Clinical Pathways

News

04/14/2022

Ellen Kurek ;

Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.

Biosimilar HD201 demonstrates...

04/14/2022

Journal of Clinical Pathways

News

Pertuzumab Added to Trastuzumab and Chemotherapy Improves Outcomes in Metastatic Breast Cancer

03/22/2022

Janelle Bradley ;

Findings from a real-world study suggest the addition of pertuzumab to trastuzumab and chemotherapy improves safety and OS for patients with metastatic breast cancer.

Findings from a real-world study...

03/22/2022

Journal of Clinical Pathways

News

Factors Associated With Exceeding Target Price Under OCM for Episodes of Breast Cancer

03/21/2022

Janelle Bradley ;

Study findings show breast cancer episodes in older women with distant metastases frequently exceeded the target price under the OCM payment methodology.

Study findings show breast...

03/21/2022

Journal of Clinical Pathways

News

Trastuzumab Biosimilars Safe, Effective Among Patients With HER2-Positive Breast Cancer

03/07/2022

Marta Rybczynski ;

Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.

Study findings show that...

03/07/2022

Journal of Clinical Pathways

News

Cost-Effectiveness of Treatment Approaches for Low-Risk Ductal Carcinoma in Situ

09/07/2021

Study findings suggest no adjuvant therapy is the most cost-effective approach for postmenopausal women who receive partial mastectomy for low-risk ductal carcinoma in situ.

Study findings suggest no...

09/07/2021

Journal of Clinical Pathways

News

Receipt of Screening Mammography Associated With Improved Outcomes Among Patients With Breast Cancer

08/26/2021

Study findings suggest that breast cancer outcomes can improve if steps are taken to increase the uptake of screening mammography.

Study findings suggest that...

08/26/2021

Journal of Clinical Pathways

News

Real-World Outcomes of Pertuzumab and T-DM1 for Metastatic Breast Cancer

08/10/2021

Study findings suggest survival among patients with ERBB2-positive metastatic breast cancer receiving pertuzumab and trastuzumab emtansine (T-DM1) in the real-world setting appears inferior to results from pivotal clinical trials.

Study findings suggest survival...

08/10/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Breast Cancer News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products